IFNG and melanoma: A combined administration of high doses of Tumor Necrosis Factor/Interferon gamma (TNF/IFNγ) through an isolation limb perfusion setting to cancer patients with sarcomas or melanoma metastases of the limbs inactivates endothelial cell αVβ3, causing endothelial cell death and selective disruption of the tumor vasculature [155].